DexCom, Inc. (DXCM) EPS CAGR:46.61%(TTM)
The eps cagr for DexCom, Inc. (DXCM) is +46.61% over the latest trailing 12-month period. EPS CAGR uses precomputed diluted earnings history where available.
The eps cagr for DexCom, Inc. (DXCM) stock is 46.61% over the past 12 months. The 3 year average growth rate is 34.47% and the 5 year cagr is 10.31%. EPS (Earnings Per Share) CAGR measures how DexCom, Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
DXCM EPS CAGR Chart
DexCom, Inc. (DXCM)
DXCM EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.46 | $2.14 | +$0.68 | +46.58% | +46.58% |
| 2024 | $1.44 | $1.46 | +$0.02 | +1.39% | +1.39% |
| 2023 | $0.88 | $1.44 | +$0.56 | +63.64% | +63.64% |
| 2022 | $0.56 | $0.88 | +$0.32 | +57.14% | +57.14% |
| 2021 | $1.31 | $0.56 | $-0.75 | -57.25% | -57.25% |
| 2020 | $0.28 | $1.31 | +$1.03 | +367.86% | +367.86% |
| 2019 | $-0.36 | $0.28 | +$0.64 | +0.00% | N/A |
| 2018 | $-0.15 | $-0.36 | $-0.21 | +0.00% | N/A |
| 2017 | $-0.20 | $-0.15 | +$0.05 | +0.00% | N/A |
| 2016 | $-0.18 | $-0.20 | $-0.02 | +0.00% | N/A |
| 2015 | $-0.07 | $-0.18 | $-0.11 | +0.00% | N/A |
| 2014 | $-0.10 | $-0.07 | +$0.03 | +0.00% | N/A |
| 2013 | $-0.20 | $-0.10 | +$0.10 | +0.00% | N/A |
| 2012 | $-0.17 | $-0.20 | $-0.03 | +0.00% | N/A |
| 2011 | $-0.24 | $-0.17 | +$0.07 | +0.00% | N/A |
| 2010 | $-0.30 | $-0.24 | +$0.06 | +0.00% | N/A |
| 2009 | $-0.47 | $-0.30 | +$0.17 | +0.00% | N/A |
| 2008 | $-0.41 | $-0.47 | $-0.06 | +0.00% | N/A |
| 2007 | $-0.43 | $-0.41 | +$0.02 | +0.00% | N/A |
| 2006 | $-0.41 | $-0.43 | $-0.02 | +0.00% | N/A |
| 2005 | $-1.53 | $-0.41 | +$1.12 | +0.00% | N/A |
| 2004 | $-1.14 | $-1.53 | $-0.39 | +0.00% | N/A |
| 2003 | $-0.94 | $-1.14 | $-0.20 | +0.00% | N/A |
| 2002 | $-0.83 | $-0.94 | $-0.11 | +0.00% | N/A |
| 2001 | $-0.57 | $-0.83 | $-0.26 | +0.00% | N/A |
Quarterly EPS — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $0.52 | -24.6% | +92.6% |
| Q4 2025 | $0.69 | -5.5% | +76.9% |
| Q3 2025 | $0.73 | +58.7% | +108.6% |
| Q2 2025 | $0.46 | +70.4% | +27.8% |
| Q1 2025 | $0.27 | -30.8% | -28.9% |
| Q4 2024 | $0.39 | +11.4% | -41.8% |
| Q3 2024 | $0.35 | -2.8% | +12.9% |
| Q2 2024 | $0.36 | -5.3% | +20.0% |
| Q1 2024 | $0.38 | -43.3% | +192.3% |
| Q4 2023 | $0.67 | +116.1% | +179.2% |
| Q3 2023 | $0.31 | +3.3% | +29.2% |
| Q2 2023 | $0.30 | +130.8% | +130.8% |
| Q1 2023 | $0.13 | -45.8% | -43.5% |
| Q4 2022 | $0.24 | +0.0% | +580.0% |
| Q3 2022 | $0.24 | +84.6% | +4.3% |
| Q2 2022 | $0.13 | -43.5% | -35.0% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach